Trial Profile
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 15 Feb 2022 Results published in the Advances in Therapy
- 27 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 Oct 2018 Status changed from recruiting to active, no longer recruiting.